Potential therapeutic applications of thyroid hormone analogs

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 9, 2007, Pages 632-640

  Brenta, Gabriela ^a,b   Danzi, Sara ^c,d   Klein, Irwin ^c,d,e  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL FRANCÉS   (Argentina)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d Department of Medicine ^*

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agonists; Analogs; Antagonists; Human disease; Thyroid hormone

Indexed keywords

3' ISOPROPYL 3,5 DIMETHYLTHYRONINE; 3,5 DIBROMO 3' (2,3 DIHYDRO 3 OXO 6 PYRIDAZINYLMETHYL)THYRONINE; 3,5 DIBROMO 4 (3' ISOPROPYL 4' HYDROXYPHENOXY)BENZOIC ACID; 3,5 DIBROMO 4 (3',5' DIISOPROPYL 4' HYDROXYPHENOXY)BENZOIC ACID; 3,5 DICHLORO 4 [(4 HYDROXY 3 ISOPROPYLPHENOXY)PHENYL]ACETIC ACID; 3,5 DIIODOTHYROPROPIONIC ACID; 3,5 DIMETHYL 4 (4' HYDROXY 3' BENZYL)BENZYLPHENOXYACETIC ACID; 3,5 DIMETHYL 4 (4' HYDROXY 3' ISOPROPYLBENZYL)PHENOXYACETIC ACID; AMIODARONE; CAPTOPRIL; GC 1; GC 14; GC 24; HORMONE ANTAGONIST; HY 4; KB 141; LEVOTHYROXINE; LIOTHYRONINE; NH 3; TETRAIODOTHYROACETIC ACID; THYROID HORMONE DERIVATIVE; THYROMIMETIC AGENT; THYROTROPIN; THYROXINE; TIRATRICOL; UNCLASSIFIED DRUG;

CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CRYSTAL STRUCTURE; DIASTOLE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GOITER; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTOLE; TACHYCARDIA; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASODILATATION; WEIGHT REDUCTION;

DRUG DESIGN; HUMANS; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; PHENYL ETHERS; PHENYLACETATES; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; THYROID HORMONES;

EID: 34548086807     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0590     Document Type: Review

References (59)

1. Edelman IS (1974) Thyroid thermogenesis. N Engl J Med 290: 1303-1308
2. Oppenheimer JH et al. (1991) Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 87: 125-132
3. Klein I and Ojamaa K (2001) Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501-509
4. Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81: 1097-1142
5. Ikeda M et al. (1994) Thyroid hormone receptor monomer, homodimer, and heterodimer (with retinoid-X receptor) contact different nucleotide sequences in thyroid hormone response elements. Endocrinology 135: 1628-1638
6. Hiroi Y et al. (2006) Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 103: 14104-14109
7. Baxter JD et al. (2001) Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol 76: 31-42
8. Harrington CR and Barger G (1927) Chemistry of thyroxine. III. Constitution and synthesis of thyroxine. Biochem J 21: 169-183
9. Gross J and Pitt-Rivers R (1952) The identification of 3:5:3′-L-triiodothyronine in human plasma. Lancet 1: 439-441
10. Maia AL et al. (2005) Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115: 2524-2533
11. Koenig R (2005) Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 15: 835-840
12. Cody V (1996) Thyroid hormone structure-function relationships. In Werner and Ingbar's The Thyroid, edn 7, 185-189 (Eds Braverman LE and Utiger RD) Philadelphia: Lippincott-Raven
13. Grover GJ et al. (2003) Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 100: 10067-10072
14. Williams GR (2000) Cloning and characterization of two novel thyroid hormone receptor β isoforms. Mol Cell Biol 20: 8329-8342
15. Lazar MA and Chin WW (1990) Nuclear thyroid hormone receptors. J Clin Invest 86: 1777-1782
16. Kahaly GJ and Dillmann WH (2005) Thyroid hormone action in the heart. Endocr Rev 26: 708-728
17. Danzi S and Klein I (2004) Thyroid hormone and the cardiovascular system. Minerva Endocrinologica 29: 139-150
18. Klein I and Danzi S: Thyroid disease and the heart. Circulation, in press
19. Hu X and Lazar MA (2000) Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab 11: 6-10
20. Nunes FM et al. (2004) Crystallization and preliminary x-ray diffraction studies of isoform ?1 of the human thyroid hormone receptor ligand-binding domain. Acta Crystallogr D Biol Crystallogr 60: 1867-1870
21. Ribeiro RC et al. (2001) Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. J Biol Chem 276: 14987-4995
22. Wagner RL et al. (1995) A structural role for hormone in the thyroid hormone receptor. Nature 378: 690-697
23. Davis PJ and Davis FB (2002) Nongenomic actions of thyroid hormone on the heart. Thyroid 12: 459-466
24. Klemperer JD et al. (1995) Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333: 1522-1527
25. Morkin E et al. (2002) Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology 97: 218-225
26. Farwell AP et al. (2006) Dynamic nongenomic actions of thyroid hormone in the developing rat brain. Endocrinology 147: 2567-2574
27. Webb P (2004) Selective activators of thyroid hormone receptors. Expert Opin Investig Drugs 13: 489-500
28. Stephan ZF et al. (1992) Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. Biochem Pharmacol 43: 1969-1974
29. Leeson PD et al. (1989) Selective thyromimetics. Cardiac-sparing thyroid hormone analogues containing 3′-arylmethyl substituents. J Med Chem 32: 320-336
30. Chopra IJ et al. (1984) Thyromimetic effects of 3,5-dimethyl,3′-isopropyl thyronine (DIMIT) and 3,5-diethyl,3′- isopropyl thyronine (DIET) in various tissues of the rat. Metabolism 33: 622-628
31. Barlow JW et al. (1989) The thyroid hormone analogue SKF L-94901: nuclear occupancy and serum binding studies. Clin Sci (Lond) 76: 495-501
32. Liang H et al. (1997) Organ-specific effects of 3,5,3′-triiodothyroacetic acid in rats. Eur J Endocrinol 137: 537-544
33. Sherman SI et al. (1997) Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 82: 2153-2158
34. Lameloise N et al. (2001) Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy. Eur J Endocrinol 144: 145-154
35. Wagner RL et al. (2001) Hormone selectivity in thyroid hormone receptors. Mol Endocrinol 15: 398-410
36. Baxter JD et al. (2004) Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 15: 154-157
37. Grover GJ et al. (2004) Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine. Endocrinology 145: 1656-1661
38. Trost SU et al. (2000) The thyroid hormone receptor-β- selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141: 3057-3064
39. Ness G et al. (1998) Effects of L-triiodothyronine and the thyromimetic L-94091 on serum lipoprotein levels and hepatic low density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochem Pharmacol 56: 121-129
40. Shin DJ and Osborne TF (2003) Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J Biol Chem 278: 34114-34118
41. Duntas LH (2002) Thyroid disease and lipids. Thyroid 12: 287-293
42. Drover VA and Agellon LB (2004) Regulation of the human cholesterol 7α-hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mice. Endocrinology 145: 574-581
43. Johansson L et al. (2005) Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 102: 10297-10302
44. Klein I (2005) Endocrine disorders and cardiovascular disease. In Braunwald's Heart Disease, edn 7, 2051-2065 (Eds Zipes DP et al.) Philadelphia: Elsevier Saunders
45. Danzi S and Klein I (2003) Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 5: 513-520
46. Iervasi G et al. (2003) Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 107: 708-713
47. Spooner PH et al. (2004) Thyroid hormone analog, DITPA, improves endothelial nitric oxide and β-adrenergic mediated vasorelaxation after myocardial infarction. J Cardiovasc Pharmacol 44: 453-459
48. 2+-ATPase and α-myosin heavy chain in rat hearts. J Clin Invest 100: 1742-1749
49. Hoit BD et al. (1997) The effects of a thyroid hormone analog on left ventricular performance and contractile and calcium cycling proteins in the baboon. Proc Assoc Am Physicians 109: 136-145
50. Silva JE and Leonard JL (1985) Regulation of rat cerebrocortical and adenohypophyseal type II 5′-deiodinase by thyroxine, triiodothyronine, and reverse triiodothyronine. Endocrinology 116: 1627-1635
51. Radetti G et al. (1997) Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid 7: 775-778
52. Jaffiol C et al. (1995) Long term follow up of medical treatment of differentiated thyroid cancer. Ann Endocrinol (Paris) 56: 119-126
53. Brenta G et al. (2003) Comparative efficacy and side effects of the treatment of euthyroid goiter with levothyroxine or triiodothyroacetic acid. J Clin Endocrinol Metab 88: 5287-5292
54. Baxter JD et al. (2002) Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 143: 517-524
55. Schapira M et al. (2000) Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 97: 1008-1013
56. Nguyen NH et al. (2002) Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 45: 3310-3320
57. Moore JMR et al. (2004) Quantitative proteomics of the thyroid hormone receptor-coregulator interactions. J Biol Chem 279: 27584-27590
58. Basaria S and Cooper DS (2005) Amiodarone and the thyroid. Am J Med 118: 706-714
59. Silva JE (2003) The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med 139: 205-213